Celgene

Abecma

View Prices
  1. Home
    2.  / 
  2. Q Code
    3.  / Abecma – Q2055

Manufacturer:

Celgene

Name:

Abecma

HCPCS Code Descriptor:

Idecabtagene vicleucel, up to 460 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose

Category:

Q Code

HCPCS:

Q2055

NDC(s):

59572-0515-02, 59572-0515-03, 59572-0515-01

Primary Type:

Oncology

Generic Status:

Single-Source

Route of Administration:

Intravenous

About:

Abecma is an Oncology drug manufactured by Celgene and administered via the Intravenous route of administration. The Q Code: Q2055 is aligned to the drug Abecma.

View Prices

Access Pricing and More By Registering

Register Now

HCPCS Added Date:

1/1/22

HCPCS Effective Date:

1/1/22

HCPCS Short Description:

Idecabtagene vicleucel car

Billing and Coding Guide:

Not Found

Patient Assistance:

https://www.celltherapy360.com/patients/